Clinical relevance of sHLA-G to premature rupture of membrane

This study aims to explore potential clinical relevance of sHLA-G to premature rupture of membrane. 75 samples of pregnancy were enrolled, including patients with preterm premature rupture of membranes (PPROM), patients with term premature rupture of membranes (TPROM) and normal pregnancy women. Level of sHLA-G in multiple sites were examined with ELISA. Lymphocytes were isolated from peripheral blood of patients with premature rupture of membrane and cultured in vitro. Lymphocytes proliferation was detected with MTT assay. Interestingly, no significant difference in the level of sHLA-G in serum and amniotic fluid was detected between PPROM group and TPROM group (P>0.05). In PPROM group and TPROM group, the level of sHLA-G in HCS lesion was higher than non-HCA lesion. Increasing incidence of HCA was associated with longer duration of membrane rupture. Regression analysis indicated duration of membrane rupture was an independent influencing factor for composites of premature rupture of fetal membranes and HCA, suggesting that pregnancy women with PROM should adopt early parturition to prevent HCA prolonged by duration of membrane rupture. MTT assay showed high concentration of HAMSC inhibited lymphocytes proliferation, while MEM-G/9Ab attenuated HAMSC inhibiting effect on lymphocytes proliferation. In summary, premature rupture of fetal membranes should be considered if decreasing level of HAMSC was detected. Inhibiting lymphocytes proliferation had promising clinical relevance in PROM.